Of note, beside an additive negative impact in patients with unfavorable cytogenetic or secondary AML, CD200 overexpression is associated with a worse prognosis also in patients with biological markers considered favorable, such as mutated NPM, Flt3 wild type, negativity of CD34 and CD56 expression and, probably, CBF AML. The gene discussed is CD200; the disease is acute myeloid leukemia.